MX9301135A - Metodo para tratar infecciones por patogeno de macrofago. - Google Patents

Metodo para tratar infecciones por patogeno de macrofago.

Info

Publication number
MX9301135A
MX9301135A MX9301135A MX9301135A MX9301135A MX 9301135 A MX9301135 A MX 9301135A MX 9301135 A MX9301135 A MX 9301135A MX 9301135 A MX9301135 A MX 9301135A MX 9301135 A MX9301135 A MX 9301135A
Authority
MX
Mexico
Prior art keywords
treating
macrophago
pathogen infections
macrophage
host cells
Prior art date
Application number
MX9301135A
Other languages
English (en)
Inventor
Steven G Reed
Original Assignee
Steven G Reed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steven G Reed filed Critical Steven G Reed
Publication of MX9301135A publication Critical patent/MX9301135A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un método para tratar a un individuo infectado con un patógeno de macrófago, que comprende administrar una cantidad efectiva de un antagonista de TGF-B. Los patógenos de macrófagos incluyen cualquier microorganismo patógeno que se multiplique dentro de las células anfitrionas macrófagas, como sus células anfitrionas exclusivas o primarias.
MX9301135A 1992-03-06 1993-03-01 Metodo para tratar infecciones por patogeno de macrofago. MX9301135A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84744192A 1992-03-06 1992-03-06

Publications (1)

Publication Number Publication Date
MX9301135A true MX9301135A (es) 1993-09-01

Family

ID=25300634

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9301135A MX9301135A (es) 1992-03-06 1993-03-01 Metodo para tratar infecciones por patogeno de macrofago.

Country Status (3)

Country Link
CA (1) CA2130995C (es)
MX (1) MX9301135A (es)
WO (1) WO1993017708A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2174868T3 (es) * 1992-10-29 2002-11-16 Celtrix Pharma Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
ATE343638T1 (de) * 1995-06-02 2006-11-15 Gilead Sciences Inc Oligonukleotidliganden mit hoher affinität für pdgf
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1

Also Published As

Publication number Publication date
WO1993017708A1 (en) 1993-09-16
CA2130995A1 (en) 1993-09-16
CA2130995C (en) 1998-12-29

Similar Documents

Publication Publication Date Title
FI834277A0 (fi) Steriliseringsbehandling med vaetesuperoxid och neutralisering av dennas restmaengder
ES2155601T3 (es) Compuestos de benzolactama sustituidos como antagonistas de la sustancia p.
ES2165862T3 (es) Procedimiento y aparato para controlar el acceso a señales digitales.
ES2153824T3 (es) Derivados de pirimidina como inhibidores de la hmg-coa reductasa.
SV1996000026A (es) Benzociclopentano oxazolidinonas que contienen heteroatomos
BR9205883A (pt) Processo para esterilizar uma superfície sólida e um material
GT197746150A (es) Nuevos agentes antielminticos y proceso para su prepracion
ES2040838T3 (es) Compuestos piperazinil-heterociclicos.
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
BR9407138A (pt) Método para esterilização de produtos
BR8101356A (pt) Processo para tratamento an aer obio de despejos organicos
BE881097A (fr) Procede perfectionne de sterilisation
UY26380A1 (es) Inhibidores de fab i
AR022023A1 (es) Combinaciones de inhibidores del transporte de acido ileo-biliar con derivados del acido fibrico para prescripciones cardiovasculares
UY25780A1 (es) Nuevos antibióticos macrólidos
BR9609069A (pt) Indução de esterelidade masculina em plantas por expressão de níveis elevados de avidina
MX9302836A (es) Proteasas alcalinas, bacterias que las producen, proceso para laproduccion de estas proteasas, usos de estas proteasas alcalinas ycomposiciones detergentes que las contienen.
BR9501975A (pt) Utilização de um extrato de pelo menos uma bactéria filamentosa nao fotossintética e nao frutificante processo de tratamento cosmético e composição cosmética
ES2180703T3 (es) Composiciones de vacunas para mamiferos que comprenden escualeno o escualano, un fosfolipido y un tensioactivo como adyuvante.
ES2101252T3 (es) Inhibidores de la proteasa del hiv utiles para el tratamiento del sida.
ES2032955T3 (es) Sal sodica anhidra cristalina de 5-cloro-3-(2-tenoil)-2-oxindol-1-carboxamida.
MX9301135A (es) Metodo para tratar infecciones por patogeno de macrofago.
ES2042868T3 (es) Un metodo de producir galidermina.
ES2184126T3 (es) Derivados de 3-mercaptoacetilamino-1,5-sustituido-2-oxo-azepan utiles como inhibidores de metaloproteinasas de la matriz.
ES2093944T3 (es) Composicion cosmetica y/o dermatologica de accion despigmentante que contiene un acido di- o tri-cafeoilquinico o una mezcla de estos.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees